17026
2018
eng
6088-6100
22
8
article
1
2018-10-26
--
--
The theranostic promise for neuroendocrine tumors in the late 2010s – Where do we stand, where do we go?
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
Theranostics
urn:nbn:de:bvb:20-opus-170264
Johns Hopkins School of Medicine
Theranostics 2018; 8(22):6088-6100. doi:10.7150/thno.30357
701983
CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International
Rudolf A. Werner
Alexander Weich
Malte Kircher
Lilja B. Solnes
Mehrbod S. Javadi
Takahiro Higuchi
Andreas K. Buck
Martin G. Pomper
Steven Rowe
Constantin Lapa
eng
uncontrolled
theranostics
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
PRRT
eng
uncontrolled
somatostatin receptor
eng
uncontrolled
peptide receptor radionuclide therapy
eng
uncontrolled
neuroendocrine tumor
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
OpenAIRE
Förderzeitraum 2018
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17026/Werner_Theranostics_2018.pdf
16699
2018
eng
article
1
2018-08-10
--
--
MI-RADS: Molecular Imaging Reporting and Data Systems – A Generalizable Framework for Targeted Radiotracers with Theranostic Implications
Both prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted positron emission tomography (PET) imaging agents for staging and restaging of prostate carcinoma or neuroendocrine tumors, respectively, are seeing rapidly expanding use. In addition to diagnostic applications, both classes of radiotracers can be used to triage patients for theranostic endoradiotherapy. While interpreting PSMA- or SSTR-targeted PET/computed tomography (CT) scans, the reader has to be aware of certain pitfalls. Adding to the complexity of the interpretation of those imaging agents, both normal biodistribution, and also false-positive and -negative findings differ between PSMA- and SSTR-targeted PET radiotracers. Herein summarized under the umbrella term molecular imaging reporting and data systems (MI-RADS), two novel RADS classifications for PSMA- and SSTR-targeted PET imaging are described (PSMA- and SSTR-RADS). Both framework systems may contribute to increase the level of a reader’s confidence and to navigate the imaging interpreter through indeterminate lesions, so that appropriate workup for equivocal findings can be pursued. Notably, PSMA- and SSTR-RADS are structured in a reciprocal fashion, i.e. if the reader is familiar with one system, the other system can readily be applied as well. In the present review we will discuss the most common pitfalls on PSMA- and SSTR-targeted PET/CT, briefly introduce PSMA- and SSTR-RADS, and define a future role of the umbrella framework MI-RADS compared to other harmonization systems.
Annals of Nuclear Medicine
0914-7187
urn:nbn:de:bvb:20-opus-166995
10.1007/s12149-018-1291-7
Johns Hopkins School of Medicine
Annals of Nuclear Medicine (2018). https://doi.org/10.1007/s12149-018-1291-7
701983
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Rudolf A. Werner
Ralph A. Bundschuh
Lena Bundschuh
Mehrbod S. Javadi
Takahiro Higuchi
Alexander Weich
Sara Sheikhbahaei
Kenneth J. Pienta
Andreas K. Buck
Martin G. Pomper
Michael A. Gorin
Constantin Lapa
Steven P. Rowe
eng
uncontrolled
PET
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
prostate cancer
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
prostate-specific membrane antigen (PSMA)
eng
uncontrolled
somatostatin receptor (SSTR)
eng
uncontrolled
positron emission tomography
eng
uncontrolled
theranostics
eng
uncontrolled
standardization
eng
uncontrolled
RADS
eng
uncontrolled
reporting and data systems
eng
uncontrolled
personalized medicine
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16699/Werner_MI-RDAS_Annals_Nuclear_Medicine_2018.pdf